Entering text into the input field will update the search result below

RedHill Biopharma Ltd (Short Float 99.55% & Short Ratio 6.68)

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • RedHill Biopharma Ltd has a Short Float99.55% & Short Ratio6.68.
  • Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease (https://clinicaltrials.gov/ct2/show/NCT04723537?term=Upamostat&draw=2&rank=1).
  • RedHill Biopharma Issued U.S. Patent 10,898,439 'Methods for treating helicobacter pylori infection' (https://www.benzinga.com/news/21/01/19319423/redhill-biopharma-issued-u-s-patent-10-898-439-methods-for-treating-helicobacter-pylori-infection).
  • Participates in "Edison Open House: Global Healthcare 2021" (27 Jan 2021 10:30 AM UK time).
  • ARK already has started a position /343,562 shares(https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_ISRAEL_INNOVATIVE_TECHNOLOGY_ETF_IZRL_HOLDINGS.pdf).

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults1, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults2, and Aemcolo® for the treatment of travelers’ diarrhea in adults3. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (II) opaganib (Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (III) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (V) RHB-107 (upamostat), a Phase 2-stage serine protease inhibitor with a planned Phase 2/3 study in symptomatic COVID-19 and targeting multiple other cancer and inflammatory gastrointestinal diseases; and (vi) RHB-106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com.

I would not  further analyse company's fundamentals, there is no time for this, you can read really a good analysis here.(https://seekingalpha.com/symbol/RDHL?s=rdhl)

I want to emphasize at 5 catalysts only now trades at $8.71 (pre market).

1. RedHill Biopharma Ltd has a Short Float 99.55% & Short Ratio 6.68,

so we may see a serious short squeeze during the next 10 days or more.

These days every market participant is really interested in the EPIC short squeeze in GameStop Corp. (GME) which now trades at $232 (pre market).

RedHill Biopharma Ltd could be next, the short flow is less, but is enormous (99.5+%).

2. News about the Upamostat, a Serine Protease Inhibitor could make things even worse for short sellers/ yet better for Longs.

3. RedHill Biopharma Issued U.S. Patent 10,898,439 'Methods for treating helicobacter pylori infection' (https://www.benzinga.com/news/21/01/19319423/redhill-biopharma-issued-u-s-patent-10-898-439-methods-for-treating-helicobacter-pylori-infection)

still no formal PR according to 


4. The upcoming participation in the "Edison Open House: Global Healthcare 2021" (27 Jan) could give extra boost.

5. Last, but not least ARK already has started a position /343,562 shares(https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_ISRAEL_INNOVATIVE_TECHNOLOGY_ETF_IZRL_HOLDINGS.pdf) and as we all know many market participants are trying to copy ARK positions and gains!!

P.S. On 14/01/2021 the company announced the closing of its previously announced underwritten offering, of 3,188,776 American Depositary Shares (ADSs) of the Company, at a price to the public of $7.84 per ADS ($25 Million), (company's website), so there is plenty of cash around ...

Analyst's Disclosure: I am/we are long RDHL, AUPH, AND MANY OTHERS.

I'm not a Professional Financial Advisor, please do your own Due Diligence before initiating any positions. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.